Analysis of enloplatin by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids.
Analytical methods were developed and validated for the determination of enloplatin (an anticancer agent) in plasma by reversed-phase LC and for platinum (an elemental component of enloplatin) in plasma, plasma ultrafiltrate (PUF) and whole blood by flameless atomic absorption spectrometry (FAAS). The LC procedure involved protein precipitation with dilute perchloric acid. The supernatant was mixed with sodium phosphate buffer and injected into the LC system. A C18 or a cyano column was used, depending on sample matrix, with UV detection at 230 nm. The LC method was linear from 0.50 to 50.0 micrograms ml-1. Inter-day and intra-day precision (RSD%) and accuracy (relative error%) were < +/- 14%. The FAAS procedure utilized a graphite furnace, a hollow cathode platinum (Pt) lamp, and Zeeman background correction. An aliquot of plasma, PUF, or whole blood was mixed with a solution of Triton X-100 and Antifoam-B and injected into the FAAS system. The FAAS method showed goodness of fit from 0.05 to 10.0 micrograms Pt/ml. Inter-day and intra-day precision and accuracy were < +/- 15%. The methods were developed to support pharmacokinetic studies in humans, dogs and rats.
Amorusi
P
P
Department of Bioanalytical Support, American Cyanamid Co., Pearl River, NY 10965.
Lessard
D
D
Bansal
S K
SK
Selinger
K
K
Yacobi
A
A
Tonelli
A P
AP
D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis* / Q000097:blood; D016190:Carboplatin / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood; D002853:Chromatography, Liquid; D004285:Dogs; D005615:Freezing; D006801:Humans; D007202:Indicators and Reagents; D010984:Platinum / Q000032:analysis* / Q000097:blood; D011786:Quality Control; D051381:Rats; D013054:Spectrophotometry, Atomic; D014462:Ultrafiltration
D000970:Antineoplastic Agents; D007202:Indicators and Reagents; D010984:Platinum; D016190:Carboplatin; C060593:enloplatin